Abstracts tagged "rheumatoid arthritis (RA) and treatment"

Abstract Number: 1619 • 2016 ACR/ARHP Annual Meeting
EARTH EXPLORER 2, a Phase IIb Exploratory Study Evaluating Efficacy and Safety of Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor-Alpha Monoclonal Antibody, and the Tumor Necrosis Factor Antagonist Golimumab in Rheumatoid Arthritis
Michael Weinblatt¹, IB McInnes², JM Kremer³, P Miranda⁴, J Vencovský⁵, A Godwood⁶, M Albulescu⁶, D Close^⁶ and GR Burmester^⁷, ¹Brigham and Women’s Hospital, Boston, MA, ²University of Glasgow, Glasgow, United Kingdom, ³The Albany Medical College, Albany, NY, ⁴Centro De Estudios Reumatológicos, Santiago, Chile, ⁵Charles University, Prague, Czech Republic, ⁶MedImmune, Cambridge, United Kingdom, ⁷Charité – University Medicine Berlin, Berlin, Germany
Background/Purpose: Mavrilimumab, a fully human monoclonal antibody targeting the granulocyte-macrophage colony-stimulating factor receptor-α, has demonstrated efficacy and safety in disease-modifying antirheumatic drug (DMARD)-inadequate responder (IR)…
Abstract Number: 1640 • 2016 ACR/ARHP Annual Meeting
Effect of BMI on Baricitinib Efficacy: Pooled Analysis from Two Phase 3 Rheumatoid Arthritis Clinical Trials
Cristiano A.F Zerbini¹, David Muram², Vipin K. Arora², Jahangir Alam² and Jeffrey R. Curtis³, ¹Centro Paulista de Investigação Clinica, São Paulo, Brazil, ²Eli Lilly and Company, Indianapolis, IN, ³Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose : The efficacy of some rheumatoid arthritis (RA) therapies is reduced among patients with high BMI. This analysis assessed the effects of baseline BMI…
Abstract Number: 1676 • 2016 ACR/ARHP Annual Meeting
Methotrexate and Anti-Tumor Necrosis Treatment Improve Endothelial Function in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Gia Deyab¹, Ingrid Hokstad², Stefan Agewall³, Torstein Lyberg⁴, Jon Elling Whist⁵, Milada Cvancarova Småstuen⁶, Gunnbjørg Hjeltnes⁷ and Ivana Hollan^8,9,10,11, ¹Department of Medical Biochemistry, Innlandet Hospital Trust, Lillehammer, Norway, ²Lillehammer Hospitat for Rheumatic Diseases, Lillehammer, Norway, ³University of Oslo, Oslo, Norway, ⁴Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway, ⁵Innlandet Hospital Trust, Lillehammer, Norway, ⁶Institution of health care - Health science PhD program, Oslo and Akershus University College, Oslo, Norway, ⁷Medicine, Innlandet Hospital Trust, Lillehammer, Norway, ⁸Harvard Medical School, Boston, MA, ⁹Department of Medicine, Brigham and Women's Hospital, Boston, MA, ¹⁰Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ¹¹Innlandet Hospital Trust, Brumunddal, Norway
Background/Purpose: Inflammatory rheumatic diseases (IRDs) are associated with accelerated atherosclerosis, which progression is related to inflammation (1). One of the first stages in atherogenesis is…
Abstract Number: 2240 • 2016 ACR/ARHP Annual Meeting
A Descriptive Analysis of Real-World Treatment Patterns in a Turkish Rheumatology Population That Continued Innovator Infliximab (Remicade) Therapy or Switched to Biosimilar Infliximab
Yusuf Yazici¹, Lin Xie², Adesuwa Ogbomo³, Dennis Parenti⁴, Kavitha Goyal⁴, Amanda Teeple⁴, Lorie A. Ellis⁵ and Ismail Simsek⁶, ¹New York University, Hospital of Joint Diseases, New York, NY, ²Director, Health Economics & Outcomes Research, STATinMED Research, Ann Arbor, MI, ³STATinMED Research Inc., Ann Arbor, MI, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵Health Economics & Outcomes Research, Janssen Scientific Affairs, LLC, Horsham, PA, ⁶Guven Hospital, Ankara, Turkey
Background/Purpose: This study examined treatment patterns in a rheumatology patient (pt) population initially prescribed innovator infliximab (IFX) that either switched to biosimilar infliximab (CT-P13) or…
Abstract Number: 2479 • 2016 ACR/ARHP Annual Meeting
Work Productivity in Early Rheumatoid Arthritis Patients Treated before and after Implementation of a Treat-to-Target Strategy
Siri Lillegraven¹, Maria Dahl Mjaavatten¹, Nina P. Sundlisater¹, Anna-Birgitte Aga¹, Inge C Olsen², Till Uhlig¹, Daniel H. Solomon³, Tore K Kvien¹, Espen A. Haavardsholm¹ and the ARCTIC Study Group, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Division of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) is a known cause of work productivity loss. Participation in work-related activities is defined as part of the primary goal of…
Abstract Number: 2494 • 2016 ACR/ARHP Annual Meeting
The Effect of Body Mass on DAS28 Response in Patients with Rheumatoid Arthritis Treated with Abatacept
J Fransen¹, L Tweehuysen², A den Broeder³, R Postema⁴, E Alemao⁵ and F van den Hoogen⁶, ¹Department of Rheumatolgy, Radboud UMC, Nijmegen, Netherlands, ²Sint Maartenskliniek Nijmegen, Nijmegen, Netherlands, ³Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ⁴Bristol-Myers Squibb, Uxbridge, United Kingdom, ⁵Bristol-Myers Squibb, Princeton, NJ, ⁶Rheumatology, Radboud UMC, Nijmegen, Netherlands
Background/Purpose: Abatacept is an effective biologic agent indicated for the treatment of RA.1 Recent studies have indicated that obesity and being overweight could reduce the…
Abstract Number: 2536 • 2016 ACR/ARHP Annual Meeting
The Performance of a Single Centre Interventional Clinic in Early Rheumatoid Arthritis
Rok Jese¹, Ales Ambrozic², Natasa Gaspersic², Alojzija Hocevar¹, Boris Lestan¹, Milena Pavic Nikolic¹, Martina Plešivčnik Novljan², Sonja Praprotnik³, Ziga Rotar¹, Alenka Šipek Dolničar¹, Dasa Suput Skvarca¹ and Matija Tomsic¹, ¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Department of Rheumatology, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia, ³Department of Rheumatology, University Medical Centre Ljubljana, Slovenia, Ljubljana, Slovenia
Background/Purpose: In early rheumatoid arthritis (RA), first assessment by a rheumatologist and/or initiation of disease-modifying anti-rheumatic drugs (DMARD) within 12 weeks of symptom onset are…
Abstract Number: 972 • 2015 ACR/ARHP Annual Meeting
A Phase 2b Study Evaluating the Efficacy and Safety of Subcutaneously Administered Tregalizumab in Subjects with Active Rheumatoid Arthritis (RA) Despite Treatment with Methotrexate (MTX)
Ronald F. van Vollenhoven¹, Edward C. Keystone², Vibeke Strand³, Cesar Pacheco-Tena⁴, Jiri Vencovsky⁵, Frank Behrens⁶, Daniela Zipp⁷, Faiza Rharbaoui⁸, Ralf Wolter⁹, Rolf-Dietrich Tiemann¹⁰, Luise Knierim¹¹, Rainer Schmeidl¹¹, Xuefei Zhou¹², Silke Aigner^8,13, Benjamin Daelken¹⁴ and Andrea Wartenberg-Demand^8,12, ¹Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ²Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Biopharmaceutical Consultant, Portola Valley, CA, ⁴Universidad Autónoma de Chihuahua, Chihuahua, Mexico, ⁵Institute of Rheumatology, Prague, Czech Republic, ⁶CIRI/Rheumatology & Fraunhofer TMP, Goethe University, Frankfurt, Germany, ⁷Landseinerstr 5, Biotest AG, Dreieich, Germany, ⁸Biotest AG, Dreieich, Germany, ⁹Corporate Clinical Research, L, Biotest AG, Dreieich, Germany, ¹⁰Data Management and Outsourcing, Biotest AG, Dreieich, Germany, ¹¹Cooperate Drug Safety, Biotest AG, Dreieich, Germany, ¹²Cooperate Clinical Research, Biotest AG, Dreieich, Germany, ¹³Landsteinerstrasse 5, Biotest AG, Dreieich, Germany, ¹⁴Project Managerment Office, Biotest Pharmaceuticals Corporation, Boca Raton, FL
Background/Purpose: In autoimmune diseases reduced numbers and functional impairment of regulatory T cells (Tregs) have been observed (1). Tregalizumab (BT-061) is a humanized, anti-CD4 mAb,…
Abstract Number: 3111 • 2015 ACR/ARHP Annual Meeting
Long-term Safety and Efficacy of Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor-α (GM–CSFR-α) Monoclonal Antibody, in Patients with Rheumatoid Arthritis (RA)
Gerd Burmester¹, IB McInnes², JM Kremer³, P Miranda⁴, J Vencovský⁵, A Godwood⁶, M Albulescu⁶, D Close⁶ and Michael Weinblatt⁷, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Glasgow Biomedical Research Centre, Glasgow, United Kingdom, ³The Albany Medical College, Albany, NY, ⁴Centro De Estudios Reumatológicos, Santiago, Chile, ⁵Institute of Rheumatology and Department of Rheumatology, Charles University, Prague, Czech Republic, ⁶MedImmune, Cambridge, United Kingdom, ⁷Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Modulating macrophage function through GM–CSF is a novel therapeutic approach for RA. Mavrilimumab, a fully human monoclonal antibody, which targets GM–CSFR-α, has demonstrated efficacy…
Abstract Number: 1002 • 2015 ACR/ARHP Annual Meeting
Aiming for Remission in Early RA: Impact on Pain during the First Year of Treatment
Ellen Moholt¹, Anna-Birgitte Aga¹, Inge C Olsen¹, Hilde Berner Hammer², Till Uhlig³, Anne Katrine Kongtorp⁴, Heidi Lunoe⁴, Elin Mejdell Styrmoe⁴, Tore K. Kvien¹, Espen A. Haavardsholm¹ and the ARCTIC study group, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Diakonhjemmet Hospital, Oslo, Norway, ⁴Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Pain is the symptom people with rheumatoid arthritis (RA) have prioritized highest for improvement [1]. Treating to target and aiming for remission in early…
Abstract Number: 3184 • 2015 ACR/ARHP Annual Meeting
Is Treat-to-Target Really Working? a Longitudinal Analysis in Biodam
Sofia Ramiro¹, Robert B.M. Landewé², Désirée van der Heijde¹, Oliver FitzGerald³, Mikkel Østergaard^4,5, Joanne Homik⁶, Ori Elkayam⁷, J Carter Thorne⁸, Margaret Larche⁹, Gianfranco Ferraccioli¹⁰, Marina Backhaus¹¹, Gilles Boire¹², Bernard Combe¹³, Thierry Schaeverbeke¹⁴, Alain Saraux¹⁵, Maxime Dougados¹⁶, Silvano Adami¹⁷, Marcello Govoni¹⁸, Luigi Sinigaglia¹⁹, Alain G. Cantagrel²⁰, Cornelia F. Allaart¹, Cheryl Barnabe²¹, Clifton O. Bingham III²², Paul P. Tak²³, Dirkjan van Schaardenburg²⁴, Hilde Berner Hammer²⁵, Rana Dadashova²⁶, Edna Hutchings²⁶, Joel Paschke²⁶ and Walter Maksymowych²⁷, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ³Rheumatology, St Vincent's University Hospital, Dublin, Ireland, ⁴Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Glostrup, Denmark, ⁵Rigshospitalet-Glostrup, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, Glostrup, Denmark, ⁶Rheumatology, University of Alberta, Edmonton, AB, Canada, ⁷Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁸University of Toronto, Toronto, ON, Canada, ⁹Rheumatology, McMaster University, Hamilton, ON, Canada, ¹⁰Rheumatology and Internal Medicine, Catholic University of the Sacred Heart, Rome, Italy, ¹¹Rheumatology/Immunology, Charite University Hospital, Berlin, Germany, ¹²Department of Medicine/Division of Rheumatology, University of Sherbrooke, Sherbrooke, QC, Canada, ¹³Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, ¹⁴Rheumatology, Pellegrin University Hospital, Bordeaux, France, ¹⁵Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ¹⁶Cochin Hospital, Paris Descartes University, Paris, France, ¹⁷University of Verona, Verona, Italy, ¹⁸University of Ferrara, Ferrara, Italy, ¹⁹Department of Rheumatology, Gaetano Pini Institute, Milan, Italy, ²⁰Dept of Rheumatology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France, ²¹Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²²Rheumatology, Johns Hopkins University, Baltimore, MD, ²³Division of Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ²⁴Rheumatology, Amsterdam Rheumatology and immunology Center, Reade, Amsterdam, Netherlands, ²⁵Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²⁶CaRE Arthritis, Edmonton, AB, Canada, ²⁷Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: A Treat-to-Target approach (T2T), treating patients with RA towards a target, either remission or low disease activity (T2T-REM or T2T-LDA), is nowadays recommended. However…
Abstract Number: 1041 • 2015 ACR/ARHP Annual Meeting
Methotrexate Monotherapy and Methotrexate Combination Therapy with Traditional and Biologic Dmards for Rheumatoid Arthritis: A Cochrane Systematic Review and Network Meta-Analysis
Glen S. Hazlewood^1,2, Cheryl Barnabe³, George A. Tomlinson⁴, Deborah Marshall⁵, Daniel Devoe⁵ and Claire Bombardier⁶, ¹Institute of Health, Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ²Medicine, University of Calgary, Calgary, AB, Canada, ³Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁴Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁵University of Calgary, Calgary, AB, Canada, ⁶18 Strathearn Blvd, University of Toronto, Toronto, ON, Canada
Background/Purpose: To compare methotrexate based disease-modifying anti-rheumatic drug (DMARD) treatments for rheumatoid arthritis in patients naïve to or after an inadequate response (IR) to methotrexate. …
Abstract Number: 3185 • 2015 ACR/ARHP Annual Meeting
A Cluster-Randomized Trial of a Behavioral Intervention to Incorporate a Treat-to-Target Approach in the Clinical Care of Rheumatoid Arthritis Patients in the United States
Leslie Harrold^1,2, George W. Reed^1,2, J. Timothy Harrington³, Christine J. Barr¹, Katherine C. Saunders¹, Allan Gibofsky⁴, Eric M. Ruderman⁵, Tmirah Haselkorn⁶, Jeffrey D. Greenberg^1,7, Ani John⁶ and Joel M. Kremer⁸, ¹Corrona, LLC, Southborough, MA, ²University of Massachusetts Medical School, Worcester, MA, ³Joiner Associates, LLC, Madison, WI, ⁴Hospital for Special Surgery, New York, NY, ⁵Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Genentech, Inc, South San Francisco, CA, ⁷NYU School of Medicine, New York, NY, ⁸Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: We report the results of a cluster-randomized behavioral intervention trial designed to assess the impact of implementing a treat-to-target (T2T) approach vs usual care…
Abstract Number: 1048 • 2015 ACR/ARHP Annual Meeting
Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor Is Effective in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis: Results from a Phase 2B Dose Ranging Study
R Westhovens¹, Rieke Alten², Dace Pavlova³, Favio Enríquez-Sosa⁴, Minodora Mazur⁵, Maria Greenwald⁶, Annegret Van der Aa⁷, Frédéric Vanhoutte⁷, Chantal Tasset⁷ and Pille Harrison⁷, ¹Skeletal Biology and Engineering Research Center, Department of Development and Regeneration, KU Leuven, Leuven, Belgium, KU Leuven, Leuven, Belgium, ²Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ³LTD M & M Centrs, Carnikava, Latvia, ⁴CLINSTILE, S.A. DE C.V, Mexico, Mexico, ⁵IMSP Institul de Cardiologie, Chisinau, Moldova, ⁶Desert Medical Advances, Palm Desert, CA, ⁷Galapagos NV, Mechelen, Belgium
Background/Purpose: Filgotinib (GLPG0634) is a novel oral, potent and selective JAK1 inhibitor that has previously demonstrated efficacy in combination with methotrexate (MTX) in treating rheumatoid…
Abstract Number: 1049 • 2015 ACR/ARHP Annual Meeting
Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor Is Effective As Monotherapy in Patients with Active Rheumatoid Arthritis: Results from a Phase 2B Dose Ranging Study
Arthur Kavanaugh¹, Lucia Ponce², Regina Cseuz³, Olga Reshetko⁴, Mykola A Stanislavchuk⁵, Maria Greenwald⁶, Annegret Van der Aa⁷, Frédéric Vanhoutte⁷, Chantal Tasset⁷ and Pille Harrison⁷, ¹University of California San Diego, La Jolla, CA, ²Consulta Privada Dra. Lucia Ponce, Temuco, Chile, ³Revita Reumatologiai Rendelo, Budapest, Indonesia, ⁴Regional Clinical Hospital, Saratov, Russia, ⁵Vinnitsa Regional Clinical Hospital n.a. Pirogov, Vinnitsa, Ukraine, ⁶Desert Medical Advances, Palm Desert, CA, ⁷Galapagos NV, Mechelen, Belgium
Background/Purpose: Filgotinib (GLPG0634) is a novel oral, potent and selective JAK1 inhibitor that has previously demonstrated efficacy in combination with methotrexate (MTX) in treating rheumatoid…

« Previous Page
1
…
3
4
5
6
7
…
10
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].